Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
The mission of Mighty Well is to help patients and their caregivers turn sickness ...
The mission of Mighty Well is to help patients ...
Connectyx Technologies Holdings Group, Inc. provides products in the healthcare ma...
Connectyx Technologies Holdings Group, Inc. pro...
Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on...
Outlook Therapeutics is a late clinical-stage b...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Join the National Investor Network and get the latest information with your interests in mind.